Pzena Investment Management LLC bought a new position in shares of Envista Holdings Co. (NYSE:NVST - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 880,177 shares of the company's stock, valued at approximately $16,979,000. Pzena Investment Management LLC owned approximately 0.51% of Envista as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Envista by 17.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 42,057 shares of the company's stock worth $811,000 after acquiring an additional 6,320 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Envista during the 4th quarter worth $10,808,000. Proficio Capital Partners LLC purchased a new position in shares of Envista in the 4th quarter worth about $358,000. M&T Bank Corp grew its position in Envista by 4.2% during the fourth quarter. M&T Bank Corp now owns 16,621 shares of the company's stock valued at $320,000 after buying an additional 676 shares during the period. Finally, Assetmark Inc. increased its holdings in Envista by 2.5% during the fourth quarter. Assetmark Inc. now owns 39,624 shares of the company's stock worth $764,000 after buying an additional 983 shares during the last quarter.
Envista Stock Performance
NYSE:NVST opened at $17.15 on Wednesday. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. The business's 50-day moving average price is $20.15 and its two-hundred day moving average price is $19.69. The stock has a market cap of $2.95 billion, a P/E ratio of -2.64, a PEG ratio of 1.27 and a beta of 1.33. Envista Holdings Co. has a twelve month low of $15.15 and a twelve month high of $23.00.
Envista (NYSE:NVST - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.01. Envista had a negative net margin of 44.56% and a positive return on equity of 3.86%. As a group, equities analysts predict that Envista Holdings Co. will post 1 EPS for the current fiscal year.
Analyst Ratings Changes
NVST has been the topic of a number of research analyst reports. Mizuho initiated coverage on shares of Envista in a research note on Wednesday, December 4th. They issued an "underperform" rating and a $20.00 target price on the stock. Morgan Stanley reduced their price objective on Envista from $20.00 to $19.00 and set an "equal weight" rating for the company in a report on Thursday, March 6th. Wells Fargo & Company set a $19.00 target price on Envista in a research note on Saturday. New Street Research set a $19.00 price target on Envista in a research note on Thursday, March 6th. Finally, JPMorgan Chase & Co. lowered their price objective on Envista from $20.00 to $19.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $20.18.
Read Our Latest Report on NVST
Envista Profile
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
